Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a radiopharmaceutical-focused company whose news flow centers on diagnostic imaging products, radiopharmaceutical pipeline progress and corporate developments. The company describes its purpose as enabling clinicians to "Find, Fight and Follow" disease, and its announcements frequently highlight advances in PET radiodiagnostics, oncology imaging agents and Alzheimer’s disease diagnostics.
News about Lantheus often covers regulatory milestones for its radiopharmaceutical pipeline. Recent releases include U.S. Food and Drug Administration (FDA) acceptance of a New Drug Application for a new formulation of its piflufolastat F 18 PSMA PET imaging agent, a PDUFA date for LNTH-2501 (Ga 68 edotreotide) for somatostatin receptor-positive neuroendocrine tumors, and FDA acceptance of an NDA for MK-6240, a tau-targeted PET imaging agent for Alzheimer’s disease. These updates provide insight into how the company is expanding its diagnostic portfolio in oncology and neurology.
Lantheus news also frequently addresses business development and portfolio shaping. The company has reported acquisitions of Evergreen Theragnostics and Life Molecular Imaging, adding assets such as OCTEVY and Neuraceq and expanding its capabilities across the radiopharmaceutical value chain. It has also announced the divestiture of its SPECT business to SHINE Technologies, along with licensing agreements such as an exclusive deal with GE HealthCare to develop, manufacture and commercialize PYLARIFY in Japan.
Investors and healthcare professionals following LNTH news can also expect quarterly earnings releases, stock repurchase program announcements, leadership transition updates and conference participation notices. Together, these items provide context on Lantheus’ financial performance, capital allocation, governance and strategic direction in the radiopharmaceutical and medical imaging space.
Lantheus Holdings (NASDAQ: LNTH) announced a strategic collaboration with SonoThera to combine its microbubble technology with SonoThera's ultrasound-guided, nonviral gene therapy platform. This partnership aims to enhance the delivery of genetic therapies, potentially offering a safer and more effective alternative to traditional viral vectors. Lantheus' microbubbles have been widely used in cardiac imaging, with over 21 million studies performed since 2001. The collaboration seeks to improve gene therapy applications through novel delivery methods, marking an innovative step in genetic medicine.
Lantheus Holdings announced the pricing of $500 million in convertible senior notes due 2027, targeting qualified institutional buyers. The company expects to net approximately $485 million after expenses, with proceeds partly used for a $150 million stock repurchase program. The notes, with a 2.625% interest rate, can be converted to common stock at a rate of 12.5291 shares per $1,000. The initial conversion price is about $79.81, a 42.5% premium over the recent stock price. The offering is set to close on December 8, 2022.
Lantheus Holdings (NASDAQ: LNTH) announced an offering of $500 million in convertible senior notes due 2027, with an option for an additional $75 million. These senior unsecured notes will be guaranteed by Lantheus Medical Imaging, and maturity is set for December 15, 2027. Proceeds will fund stock repurchases and general corporate purposes. The board has authorized up to $150 million for repurchases, with $75 million allocated for buying shares from note purchasers. The offering is limited to qualified institutional buyers under Rule 144A.
Lantheus Holdings (NASDAQ: LNTH) has appointed Amanda Morgan as Senior Vice President, Commercial, effective November 29, 2022. Reporting to COO Paul Blanchfield, Morgan will oversee all commercial activities, including Sales, Marketing, and Market Access. With over 20 years in healthcare, she previously served as Chief Revenue and Customer Officer at Acadia Pharmaceuticals and held senior roles at Shire Plc. Her leadership is anticipated to enhance the company's commercial strategy and patient outcomes.
Lantheus Holdings (NASDAQ: LNTH) announced the approval of the Import Drug License for DEFINITY, a diagnostic ultrasound enhancing agent, by China's National Medical Products Administration. DEFINITY is indicated for patients with suboptimal echocardiograms, helping to identify the left ventricular endocardial border. The commercialization will be handled by CR Double-Crane in China. This move aims to address the growing incidence of cardiovascular disease in China, where 20% of adults are affected.
Lantheus Holdings (NASDAQ: LNTH) has entered into a strategic collaboration with POINT Biopharma Global (NASDAQ: PNT) for exclusive worldwide rights to two late-stage radiopharmaceuticals, PNT2002 and PNT2003. Lantheus will pay $260 million upfront, with potential milestone payments reaching approximately $1.8 billion. The collaboration aims to enhance Lantheus’ prostate cancer portfolio and drive long-term revenue growth. Both companies will fund and complete clinical trials, with Lantheus retaining commercialization rights post-FDA approval.
Lantheus Holdings (NASDAQ: LNTH) announced that CFO Bob Marshall will present at the Jefferies London Healthcare Conference on November 16, 2022, at 8:00 a.m. GMT (3 a.m. EST). The live webcast can be accessed on the company's website, with a replay available for 30 days post-presentation. Lantheus has over 65 years of experience in improving patient outcomes through diagnostics, radiotherapeutics, and AI solutions, aimed at helping clinicians Find, Fight, and Follow disease. The company is based in Massachusetts, with additional offices in New Jersey, Canada, and Sweden.
Lantheus reported a remarkable third quarter for 2022, achieving worldwide revenue of $239.3 million, marking a 134.4% increase year-over-year. The company's GAAP net income surged to $61.2 million or $0.86 per fully diluted share, compared to a loss of $13.4 million in the same quarter of 2021. Adjusted fully diluted EPS was $0.99, up from $0.08 a year earlier. With operating cash flow at $93.6 million and free cash flow of $87.5 million, Lantheus also provided positive guidance for Q4 and updated full-year 2022 expectations.
Lantheus Holdings (NASDAQ: LNTH) announced a conference call and webcast for November 3, 2022, at 8:00 a.m. ET to discuss Q3 2022 financial and operating results. The company encourages participants to register online ahead of time to avoid delays. A replay will be available approximately two hours post-event for 30 days. Lantheus, with over 60 years of experience, focuses on improving patient outcomes through diagnostics and AI solutions in healthcare.
Lantheus Holdings (NASDAQ: LNTH) presented AI data at the 2022 EANM Annual Meeting in Barcelona, showcasing the clinical utility of PYLARIFY AI for prostate cancer treatment. Key highlights include a top-rated presentation demonstrating a strong association between automated PSMA scores and PSA response in prostate cancer, indicating that a quantitative PSMA score can effectively assess treatment response. The company also unveiled new adaptive methodologies improving tumor burden quantification in PSMA PET/CT imaging. PYLARIFY AI is FDA-cleared and aims to enhance diagnostic efficiency.